# Guilin Pharmaceutical Co., Ltd. – FDA Inspection, Aug 18, 2023

Source: https://www.keypedia.com/records/fda_inspections/guilin-pharmaceutical-co-ltd/330fef8b-c36c-41fe-beb1-3e7344d42db6
Source feed: FDA_Inspections

> FDA inspection 1217732 of Guilin Pharmaceutical Co., Ltd., August 18, 2023. Classification: No Action Indicated (NAI). 4 citations under 21 CFR part 211. Form 483 issued. 3 other FDA inspections on record for this company.

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1217732
- Company Name: Guilin Pharmaceutical Co., Ltd.
- Inspection Date: 2023-08-18
- Classification: No Action Indicated (NAI)
- Classification Code: NAI
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Center: Human Drugs
- Office Name: Center for Drug Evaluation and Research
- Citation Count: 4

## Related Documents

- [FDA Inspection 1061489 - 2018-07-19](https://www.keypedia.com/records/fda_inspections/guilin-pharmaceutical-co-ltd/b4eb333f-6776-4112-b186-4dad9d53ea0e)
- FDA Inspection 920262 - 2015-03-13
- FDA Inspection 748950 - 2011-09-02

## Related Officers

- [Issuing Officer](https://www.keypedia.com/people/hung-h-do/580f78ba-ed7a-4c10-8f4c-a99d0af7206e)
- [Issuing Officer](https://www.keypedia.com/people/rowena-s-nguyen/ae39318e-1653-467c-94cc-26f8929441ac)

Company: https://www.keypedia.com/companies/guilin-pharmaceutical-co-ltd/8a53776f-b81a-417d-b1c5-ea1cd2d0b0a8

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c